Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 Immunogenicity and Reactogenicity in Burkina Faso
NCT01577771Phase 4Completed
- Sponsor
- Agence de Médecine Préventive
- Start
- Feb 2013
- Primary completion
- May 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Prevnar 13 in pneumococcal infection, sponsored by Agence de Médecine Préventive. Started Feb 2013; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01577771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01577771.